Targeting RNA transcription and translation in ovarian inhibitor CDKI-73

Oncotarget

5, 7691-7704

DOI: 10.18632/oncotarget.2296

Citation Report

#	Article	IF	Citations
1	Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells. Cancer Letters, 2015, 357, 612-623.	3.2	40
2	Modifications of RNA polymerase II CTD: Connections to the histone code and cellular function. Biotechnology Advances, 2015, 33, 856-872.	6.0	34
3	Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors. Cancers, 2015, 7, 179-237.	1.7	257
4	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 953-970.	2.4	38
5	An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis. European Journal of Medicinal Chemistry, 2015, 103, 539-550.	2.6	25
6	P-TEFb Kinase Activity Is Essential for Global Transcription, Resumption of Meiosis and Embryonic Genome Activation in Pig. PLoS ONE, 2016, 11, e0152254.	1.1	4
7	Cyclic Dependent Kinase (CDK): Role in Cancer Pathogenesis and as Drug Target in Cancer Therapeutics. Journal of Cancer Science & Therapy, 2016, 8, .	1.7	9
8	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 2016, 59, 8667-8684.	2.9	121
9	Mnk1 (Mitogen-Activated Protein Kinaseâ€“Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice. Hypertension, 2016, 68, 1393-1399.	1.3	30
10	Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica, 2016, 37, 1481-1489.	2.8	30
11	Targeting CDK9: a promising therapeutic opportunity in prostate cancer. Endocrine-Related Cancer, 2016, 23, T211-T226.	1.6	57
12	Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. Future Medicinal Chemistry, 2016, 8, 2047-2076.	1.1	10
13	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. MedChemComm, 2016, 7, 1580-1586.	3.5	19
14	Spectroscopic studies on the binding interaction of phenothiazinium dyes, azure A and azure B to double stranded RNA polynucleotides. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2016, 152, 417-425.	2.0	26
15	Inhibitors of cyclin-dependent kinases as cancer therapeutics. , 2017, 173, 83-105.		278
16	Targeting Cyclin-Dependent Kinases in Ovarian Cancer. Cancer Investigation, 2017, 35, 367-376.	0.6	20
17	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	2.9	40
18	Effects of CDK inhibitors on the maturation, transcription, and MPF activity of porcine oocytes. Reproductive Biology, 2017, 17, 320-326.	0.9	10

#	Article	IF	Citations
19	Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells. Biochemical and Biophysical Research Communications, 2017, 482, 536-541.	1.0	7
20	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	2.9	47
21	Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer. , 2017, , 202-280.		4
22	Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight, 2018, 3, .	2.3	19
23	Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology, 2019, 13, 2178-2193.	2.1	39
24	Hepatocellular Carcinoma: Etiology and Current and Future Drugs. Journal of Clinical and Experimental Hepatology, 2019, 9, 221-232.	0.4	167
25	Cyclinâ€dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. FASEB Journal, 2019, 33, 5990-6000.	0.2	47
26	CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational New Drugs, 2019, 37, 625-635.	1.2	26
27	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. Haematologica, 2020, 105, 1021-1031.	1.7	6
28	Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. Bioorganic Chemistry, 2020, 104, 104345.	2.0	15
29	CDKI-73 Is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion. Cells, 2020, 9, 372.	1.8	6
30	Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma. Cancers, 2020, 12, 304.	1.7	13
31	CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Frontiers in Oncology, 2021, 11, 678559.	1.3	62
32	Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation. European Journal of Medicinal Chemistry, 2021, 218, 113391.	2.6	5
33	Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story. Current Chemical Biology, 2021, 15, 139-162.	0.2	0
34	A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase IIâ€"Biological functions and inhibitors. Bioorganic Chemistry, 2020, 104, 104318.	2.0	6
35	Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget, 2016, 7, 56811-56825.	0.8	20
36	Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. Oncotarget, 2015, 6, 14926-14939.	0.8	52

#	Article	IF	Citations
37	The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer. Oncotarget, 2016, 7, 2105-2112.	0.8	9
38	CDK9 as an Appealing Target for Therapeutic Interventions. Current Drug Targets, 2019, 20, 453-464.	1.0	29
39	Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity. Medicinal Chemistry, 2019, 15, 602-623.	0.7	7
40	Development and In Vitro Evaluation of 5-Fluorouracil-Eluting Stents for the Treatment of Colorectal Cancer and Cancer-Related Obstruction. Pharmaceutics, 2021, 13, 17.	2.0	16
41	Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive longâ€'term BRAF inhibition. International Journal of Oncology, 2020, 56, 1429-1441.	1.4	10
43	CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. American Journal of Cancer Research, 2020, 10, 1140-1155.	1.4	9
44	Expression of CDK9 in endometrial cancer tissues and its effect on the proliferation of HEC-1B. Open Life Sciences, 2021, 16, 1341-1346.	0.6	2
45	CDK9 inhibitors in cancer research. RSC Medicinal Chemistry, 2022, 13, 688-710.	1.7	10
46	LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization. Melanoma Research, 0, Publish Ahead of Print, .	0.6	0
47	Discovery of Novel and Potent Inhibitors of Cyclinâ€Dependent Kinases 7 and 9: Design, Synthesis, Structureâ€Activity Relationship Analysis and Biological Evaluation. ChemMedChem, 0, , .	1.6	3